Kymera TherapeuticsKYMR
KYMR
About: Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Employees: 218
0
Funds holding %
of 7,433 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
206% more call options, than puts
Call options by funds: $7.68M | Put options by funds: $2.51M
150% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 26
72% more capital invested
Capital invested by funds: $2B [Q1] → $3.43B (+$1.44B) [Q2]
44% more funds holding in top 10
Funds holding in top 10: 9 [Q1] → 13 (+4) [Q2]
39% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 49
20% more funds holding
Funds holding: 172 [Q1] → 207 (+35) [Q2]
8.6% more ownership
Funds ownership: 112.12% [Q1] → 120.72% (+8.6%) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$53
21%
upside
Avg. target
$62
40%
upside
High target
$79
80%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Jeff Jones | 21%upside $53 | Outperform Maintained | 27 Jun 2025 |
Wells Fargo Derek Archila | 21%upside $53 | Overweight Maintained | 26 Jun 2025 |
HC Wainwright & Co. Andrew Fein | 37%upside $60 | Buy Maintained | 26 Jun 2025 |
B. Riley Securities Kalpit Patel | 37%upside $60 | Buy Upgraded | 3 Jun 2025 |
Morgan Stanley James Quigley | 80%upside $79 | Overweight Upgraded | 3 Jun 2025 |
Financial journalist opinion
Based on 5 articles about KYMR published over the past 30 days
Positive
Kiplinger
2 weeks ago
The Best Small-Cap Stocks to Buy Now
Wall Street's best small-cap stocks to buy include biotech, real estate and software names.
Neutral
Seeking Alpha
2 weeks ago
Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q2 2025 Earnings Conference Call August 11, 2025 8:30 AM ET Company Participants Bruce N. Jacobs - Chief Financial Officer Jared A.
Negative
Zacks Investment Research
2 weeks ago
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.58 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile
Positive
Zacks Investment Research
3 weeks ago
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
1 month ago
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.
Neutral
GlobeNewsWire
2 months ago
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $44.00 per share and the pre-funded warrants are being sold at a public offering price of $43.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 855,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $250.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters' option to purchase additional shares. All of the securities being sold in this offering are being offered by Kymera. The offering is expected to close on June 30, 2025, subject to the satisfaction of customary closing conditions.
Neutral
Zacks Investment Research
2 months ago
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.
Neutral
GlobeNewsWire
2 months ago
Kymera Therapeutics Announces Proposed Public Offering
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Positive
Proactive Investors
2 months ago
Gilead partners with Kymera to develop novel cancer therapy
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) and Kymera Therapeutics (NASDAQ:KYMR) have entered into an exclusive option and license agreement focused on developing a novel cancer treatment targeting cyclin-dependent kinase 2 (CDK2), a protein that plays a key role in tumor growth. This collaboration aims to accelerate the development and commercialization of a new class of drugs called molecular glue degraders (MDGs), which work by selectively removing the CDK2 protein from cancer cells rather than merely inhibiting its function.
Charts implemented using Lightweight Charts™